PDCD1 and neoplasm: In preclinical animal models, the host response to 5-FU cancer treatment and anti-PD1 immunotherapy was particularly improved by administrating C.B. Our study uncovers C.B as a potential anti-cancer agent regulating important aspects of drug resistance and immune surveillance escape during tumor treatment and provides insight into potential cancer treatment strategies.